“Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis”. Open Access Indonesian Journal of Medical Reviews, vol. 5, no. 5, Sept. 2025, pp. 607-26, https://doi.org/10.37275/oaijmr.v5i5.780.